-
1.发明授权Plasma phospholipid transfer protein (PLTP) deficiency represents an anti-atherogenic state and PLTP inhibitor has anti-atherosclerosis action 失效血浆磷脂转运蛋白（PLTP）缺乏代表抗动脉粥样硬化状态，PLTP抑制剂具有抗动脉粥样硬化作用公开(公告)号：US06953671B2
公开(公告)日：2005-10-11
申请号：US09792448
申请日：2001-02-23
Applicant: Xian-Cheng Jiang , Alan R. Tall
Inventor： Xian-Cheng Jiang , Alan R. Tall
CPC classification number: G01N33/5067 , A01K67/0276 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0362 , C12N15/8509 , C12N2799/022 , G01N33/5008 , G01N33/5076 , G01N33/6893 , G01N33/92 , G01N2800/044 , G01N2800/323
Abstract: This invention provides methods of decreasing apolipoprotein B-containing lipoprotein and of treating atherosclerotic diseases and dyslipidemic diseases by reducing plasma phospholipid transfer protein activity, and methods of identifying chemical compounds for use in such treatments.
Abstract translation: 本发明提供降低载脂蛋白B的脂蛋白并通过降低血浆磷脂转运蛋白活性来治疗动脉粥样硬化疾病和血脂异常疾病的方法，以及鉴定用于这种治疗的化合物的方法。
-
Patent Agency Ranking
2.发明申请ENZYMATIC METHODS FOR MEASURING PLASMA AND TISSUE SPHINGOMYLELIN AND PHOSPHATIDYLCHOLINE 审中-公开用于测量血浆和组织SPHINGOMYLELIN和磷脂酰胆碱的酶法公开(公告)号：US20090148877A1
公开(公告)日：2009-06-11
申请号：US12097380
申请日：2006-12-13
Applicant: Xian-Cheng Jiang , Mohammad Reza Hojjati
Inventor： Xian-Cheng Jiang , Mohammad Reza Hojjati
IPC: C12Q1/42
CPC classification number: C12Q1/44 , C12Q1/28 , C12Q1/42 , C12Q2326/96 , G01N2333/916 , G01N2405/04 , G01N2405/08
Abstract: A method for measuring sphingomyelin and phosphatidylcholine comprising incubating sphingomyelin and phosphatidylcholine with bacterial sphingomyelinase and bacterial phospholipase D, alkaline phosphatase, choline oxidase, peroxidase, N-Ethyl-N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline, and 4-aminoantipyrine, preferably for about 45 minutes. A blue dye is generated.
Abstract translation: 一种测定鞘磷脂和磷脂酰胆碱的方法，包括用细菌鞘磷脂酶和细菌磷脂酶D，碱性磷酸酶，胆碱氧化酶，过氧化物酶，N-乙基-N-（2-羟基-3-磺基丙基）-3,5-二甲氧基苯胺孵育鞘磷脂和磷脂酰胆碱， 和4-氨基安替比林，优选约45分钟。 产生蓝色染料。
-
3.发明申请SERINE PALMITOYLCOA TRANSFERASE (SPT) INHIBITION BY MYRIOCIN OR GENETIC DEFICIENCY DECREASES CHOLESTEROL ABSORPTION 审中-公开丝氨酸转氨酶（SPT）抑制MYRIOCIN或遗传缺陷减少胆固醇吸收公开(公告)号：US20090264528A1
公开(公告)日：2009-10-22
申请号：US12425818
申请日：2009-04-17
Applicant: Xian-Cheng Jiang , Zhiqiang Li
Inventor： Xian-Cheng Jiang , Zhiqiang Li
IPC: A61K31/201 , G01N33/68 , G01N33/92 , C12Q1/02
CPC classification number: A61K31/201 , G01N33/92
Abstract: A first aspect of the invention provides a method of screening cholesterol absorption inhibitors, including: administering to a mammal a biologically effective amount of a candidate SPT inhibitor; and determining whether an amount at least one cholesterol absorption indicator protein in the intestine has changed after the administering step.
Abstract translation: 本发明的第一方面提供了一种筛选胆固醇吸收抑制剂的方法，包括：向哺乳动物施用生物有效量的候选SPT抑制剂; 以及在施用步骤之后确定肠中至少一种胆固醇吸收指示蛋白的量是否已经改变。
-
公开(公告)号：US20080249174A1
公开(公告)日：2008-10-09
申请号：US12066139
申请日：2006-09-07
Applicant: Xian-Cheng Jiang , Mohammad Reza Hojjati
Inventor： Xian-Cheng Jiang , Mohammad Reza Hojjati
IPC: A61K31/197 , A01K67/027 , A61P9/10 , G01N33/53
CPC classification number: C12N15/8509 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0375 , C12N9/1029 , G01N33/5088
Abstract: The present invention provides an animal model for atherosclerosis and a transgenic knockout animal. Methods for preventing and/or treating atherosclerosis are also provided. More specifically, the present invention provides methods of preventing and/or treating atherosclerosis by administering to a subject in need thereof an inhibitor of Serine palmitoyl-CoA transferase (SPT) or its subunit.
Abstract translation: 本发明提供动脉粥样硬化的动物模型和转基因敲除动物。 还提供了预防和/或治疗动脉粥样硬化的方法。 更具体地，本发明提供了通过向有需要的受试者施用丝氨酸棕榈酰辅酶A转移酶（SPT）或其亚单位的抑制剂来预防和/或治疗动脉粥样硬化的方法。
-
公开(公告)号：US07618784B2
公开(公告)日：2009-11-17
申请号：US10279787
申请日：2002-10-23
Applicant: Robert W. Brocia , Xian-Cheng Jiang
Inventor： Robert W. Brocia , Xian-Cheng Jiang
IPC: G01N33/53
CPC classification number: G01N33/92 , G01N33/542 , G01N2500/04 , G01N2800/044
Abstract: Improved methods for assaying the activity of phospholipid transfer protein (PLTP) enhance the signal-to-noise ratio by providing the substrate in donor particles with an aqueous core in the presence of suitable osmotic pressure.
Abstract translation: 用于测定磷脂转移蛋白（PLTP）的活性的改进方法通过在合适的渗透压存在下在供体颗粒中提供含水核心的底物来提高信噪比。
-
6.发明申请SPHINGOMYELIN SYNTHASE 2 (SMS2) DEFICIENCY ATTENUATES NFkB ACTIVATION, A POTENTIAL ANTI-ATHEROGENIC PROPERTY 审中-公开SPHINGOMYELIN SYNTHASE 2（SMS2）缺乏NFκB激活，潜在的抗原性公开(公告)号：US20090264514A1
公开(公告)日：2009-10-22
申请号：US12426324
申请日：2009-04-20
Applicant: Xian-Cheng Jiang , Tiruneh K. Hallemariam
Inventor： Xian-Cheng Jiang , Tiruneh K. Hallemariam
IPC: A61K31/7105 , C12Q1/02 , C12N9/99
CPC classification number: A61K31/7105 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/03 , C12N9/1288 , C12N15/8509 , C12Q1/48 , G01N2333/9129 , G01N2500/10
Abstract: The present invention is directed to a method of screening for NFκB inhibiting agents, the method including the steps of administering a biologically effective amount of a candidate SMS2 inhibitor to at least one cell; and determining whether the candidate SMS2 inhibitor inhibits NFκB.
Abstract translation: 本发明涉及筛选NFκB抑制剂的方法，所述方法包括以下步骤：向至少一个细胞施用生物有效量的候选SMS2抑制剂; 以及确定所述候选SMS2抑制剂是否抑制NFkappaB。
-
-
-
-
-
Search Results
6
records
(took 0.014 seconds)
